515635329	515635329	CD	B-NP	O
|	|	NN	I-NP	O
PMH	PMH	NN	I-NP	O
|	|	NN	I-NP	O
31062630	31062630	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
1585636	1585636	CD	B-NP	O
|	|	CC	I-NP	O
10/6/2003	10/6/2003	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
ANGINA	ANGINA	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/6/2003	10/6/2003	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
4/23/2003	4/23/2003	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
JOSEF	JOSEF	NNP	B-NP	O
CROTTEAU	CROTTEAU	NNP	I-NP	O
M.D.	M.D.	NNP	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
Watylake	Watylake	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
Cardiology	Cardiology	NNP	I-NP	O
Service	Service	NNP	I-NP	O
and	and	CC	O	O
Coronary	Coronary	NNP	B-NP	O
Care	Care	NNP	I-NP	O
Service	Service	NNP	I-NP	O
.	.	.	O	O

PRINCIPAL	PRINCIPAL	JJ	B-NP	O
DIAGNOSES	DIAGNOSES	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Myocardial	Myocardial	JJ	B-NP	O
infarction	infarction	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Ventricular	Ventricular	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
arrest	arrest	NN	I-NP	O
.	.	.	O	O

OTHER	OTHER	NN	B-NP	O
DIAGNOSES	DIAGNOSES	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Atrial	Atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
with	with	IN	B-PP	O
rapid	rapid	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
response	response	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Diabetes	Diabetes	NN	B-NP	O
type	type	NN	I-NP	O
2	2	CD	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Peripheral	Peripheral	JJ	B-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Chronic	Chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Depression	Depression	NN	B-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Hypercholesterolemia	Hypercholesterolemia	NN	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

COPD	COPD	NN	B-NP	O
-LRB-	-LRB-	HYPH	I-NP	O
chronic	chronic	JJ	I-NP	O
obstructive	obstructive	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
disease	disease	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

History	History	NN	B-NP	O
of	of	IN	B-PP	O
GI	GI	NN	B-NP	O
bleed	bleed	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Obstructive	Obstructive	JJ	B-NP	O
sleep	sleep	NN	I-NP	O
apnea	apnea	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Status	Status	NNP	B-NP	O
post	post	NN	I-NP	O
cholecystectomy	cholecystectomy	NN	I-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Status	Status	NNP	B-NP	O
post	post	VBD	B-VP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
bypass	bypass	IN	B-PP	O
graft	graft	NN	B-NP	O
with	with	IN	B-PP	O
aortic	aortic	JJ	B-NP	O
valve	valve	NN	I-NP	O
replacement	replacement	NN	I-NP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

History	History	NN	B-NP	O
of	of	IN	B-PP	O
transfusion	transfusion	NN	B-NP	O
reaction	reaction	NN	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
60-year-old	60-year-old	JJ	I-NP	O
male	male	NN	I-NP	O
with	with	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
bypass	bypass	IN	B-PP	O
graft	graft	NN	B-NP	O
in	in	IN	B-PP	O
1982	1982	CD	B-NP	O
,	,	,	O	O
also	also	RB	B-ADVP	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
Bjork-Shiley	Bjork-Shiley	JJ	I-NP	O
aortic	aortic	JJ	I-NP	O
valve	valve	NN	I-NP	O
replacement	replacement	NN	I-NP	O
for	for	IN	B-PP	O
bicuspid	bicuspid	JJ	B-NP	O
aortic	aortic	JJ	I-NP	O
valve	valve	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
redo	redo	VBP	B-VP	O
CABG	CABG	NN	B-NP	B-protein
in	in	IN	B-PP	O
1995	1995	CD	B-NP	O
with	with	IN	B-PP	O
SVG	SVG	NN	B-NP	O
to	to	TO	B-PP	O
OM2	OM2	NN	B-NP	B-protein
and	and	CC	I-NP	O
SVG	SVG	NN	I-NP	O
to	to	TO	B-PP	O
LAD	LAD	NN	B-NP	B-protein
,	,	,	O	O
who	who	WP	B-NP	O
presented	present	VBD	B-VP	O
to	to	TO	B-PP	O
Nalcon	Nalcon	NNP	B-NP	O
Memorial	Memorial	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
after	after	IN	B-PP	O
developing	develop	VBG	B-VP	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
unrefractory	unrefractory	JJ	B-ADJP	O
to	to	TO	B-PP	O
nitroglycerin	nitroglycerin	NN	B-NP	B-protein
.	.	.	O	O

En	En	NN	B-NP	O
route	route	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
ER	ER	NN	I-NP	B-protein
,	,	,	O	O
he	he	PRP	B-NP	O
suffered	suffer	VBD	B-VP	O
a	a	DT	B-NP	O
ventricular	ventricular	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
arrest	arrest	NN	I-NP	O
,	,	,	O	O
was	be	VBD	B-VP	O
defibrillated	defibrillate	VBN	I-VP	O
x1	x1	NN	B-NP	O
with	with	IN	B-PP	O
120	120	CD	B-NP	O
Joules	Joule	NNS	I-NP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
rhythm	rhythm	NN	I-NP	O
of	of	IN	B-PP	O
pulseless	pulseless	JJ	B-NP	O
electrical	electrical	JJ	I-NP	O
activity	activity	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
then	then	RB	B-ADVP	O
received	receive	VBD	B-VP	O
fluids	fluid	NNS	B-NP	O
and	and	CC	O	O
lidocaine	lidocaine	NN	B-NP	O
bolus	bolus	NN	I-NP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
recovered	recover	VBD	B-VP	O
his	his	PRP$	B-NP	O
pulse	pulse	NN	I-NP	O
and	and	CC	I-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
intubated	intubate	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
field	field	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
AVR	AVR	NN	I-NP	O
Bjork-Shiley	Bjork-Shiley	NN	I-NP	O
and	and	CC	O	O
saphenous	saphenous	JJ	B-NP	O
vein	vein	NN	I-NP	O
graft	graft	NN	I-NP	O
to	to	TO	B-PP	O
LAD	LAD	NN	B-NP	O
and	and	CC	O	O
left	leave	VBD	B-VP	O
circumflex	circumflex	NN	B-NP	O
sequential	sequential	JJ	I-NP	O
grafting	grafting	NN	I-NP	O
,	,	,	O	O
original	original	JJ	B-NP	O
surgery	surgery	NN	I-NP	O
in	in	IN	B-PP	O
1982	1982	CD	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
1985	1985	CD	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
reoperation	reoperation	NN	B-NP	O
with	with	IN	B-PP	O
saphenous	saphenous	JJ	B-NP	O
vein	vein	NN	I-NP	O
graft	graft	NN	I-NP	O
to	to	TO	B-PP	O
LAD	LAD	NN	B-NP	O
and	and	CC	O	O
saphenous	saphenous	JJ	B-NP	O
vein	vein	NN	I-NP	O
graft	graft	NN	I-NP	O
to	to	TO	B-PP	O
OM2	OM2	NN	B-NP	B-protein
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
multiple	multiple	JJ	B-NP	O
admissions	admission	NNS	I-NP	O
to	to	TO	B-PP	O
Estatewentlung	Estatewentlung	NNP	B-NP	O
Lufirm	Lufirm	NNP	I-NP	O
Community	Community	NNP	I-NP	O
Medical	Medical	NNP	I-NP	O
Center	Center	NNP	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
year	year	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
September	September	NNP	B-NP	O
2003	2003	CD	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
ruled	rule	VBD	B-VP	O
in	in	RP	B-PRT	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
non-ST	non-ST	JJ	I-NP	O
elevation	elevation	NN	I-NP	O
myocardial	myocardial	JJ	I-NP	O
infarction	infarction	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
catheterization	catheterization	NN	I-NP	B-protein
lab	lab	NN	I-NP	I-protein
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
cath	cath	NN	I-NP	B-protein
lab	lab	NN	I-NP	I-protein
in	in	IN	B-PP	O
September	September	NNP	B-NP	O
2003	2003	CD	I-NP	O
,	,	,	O	O
at	at	IN	B-PP	O
Dotonh	Dotonh	NNP	B-NP	O
/	/	SYM	I-NP	O
Medical	Medical	JJ	I-NP	O
Center	Center	NN	I-NP	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
main	main	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
tight	tight	JJ	I-NP	O
ostial	ostial	JJ	I-NP	O
lesion	lesion	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
saphenous	saphenous	JJ	B-NP	O
vein	vein	NN	I-NP	O
graft	graft	NN	I-NP	O
to	to	TO	B-PP	O
LAD	LAD	NN	B-NP	B-protein
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
patent	patent	JJ	B-NP	O
,	,	,	I-NP	O
saphenous	saphenous	JJ	I-NP	O
vein	vein	NN	I-NP	O
graft	graft	NN	I-NP	O
to	to	TO	B-PP	O
OM2	OM2	NN	B-NP	B-protein
was	be	VBD	B-VP	O
patent	patent	NN	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
tight	tight	JJ	I-NP	O
95	95	CD	I-NP	O
%	%	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
proximally	proximally	RB	B-ADVP	O
in	in	IN	B-PP	O
OM2	OM2	NN	B-NP	B-protein
at	at	IN	B-PP	O
the	the	DT	B-NP	O
touchdown	touchdown	NN	I-NP	B-DNA
site	site	NN	I-NP	I-DNA
inhibiting	inhibit	VBG	B-VP	O
retrograde	retrograde	JJ	B-NP	O
profusion	profusion	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
determined	determine	VBN	I-VP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
that	that	IN	B-SBAR	O
PCI	PCI	NN	B-NP	B-protein
would	would	MD	B-VP	O
be	be	VB	I-VP	O
inappropriate	inappropriate	JJ	B-ADJP	O
.	.	.	O	O

At	At	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
and	and	CC	I-NP	O
echo	echo	NN	I-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	B-protein
of	of	IN	B-PP	O
25	25	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
moderate	moderate	JJ	B-NP	O
mitral	mitral	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
and	and	CC	O	O
right	right	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
systolic	systolic	JJ	I-NP	O
pressures	pressure	NNS	I-NP	O
of	of	IN	B-PP	O
47	47	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
medically	medically	RB	I-VP	O
managed	manage	VBN	I-VP	O
on	on	IN	B-PP	O
nitrates	nitrate	NNS	B-NP	O
,	,	,	O	O
an	an	DT	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
,	,	,	O	O
beta-blocker	beta-blocker	NN	B-NP	O
,	,	,	O	O
digoxin	digoxin	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Lasix	Lasix	NNP	B-NP	O
.	.	.	O	O

Per	Per	IN	B-PP	O
his	his	PRP$	B-NP	O
wife	wife	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
doing	do	VBG	I-VP	O
well	well	RB	B-ADVP	O
since	since	IN	B-PP	O
April	April	NNP	B-NP	O
of	of	IN	B-PP	O
2003	2003	CD	B-NP	O
,	,	,	O	O
only	only	RB	B-NP	O
sublingual	sublingual	JJ	I-NP	O
nitrogens	nitrogen	NNS	I-NP	O
on	on	IN	B-PP	O
occasion	occasion	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
today	today	NN	B-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
he	he	PRP	B-NP	O
ate	eat	VBD	B-VP	O
lunch	lunch	NN	B-NP	O
with	with	IN	B-PP	O
his	his	PRP$	B-NP	O
son	son	NN	I-NP	O
and	and	CC	O	O
then	then	RB	B-ADVP	O
developed	develop	VBD	B-VP	O
his	his	PRP$	B-NP	O
typical	typical	JJ	I-NP	O
substernal	substernal	JJ	I-NP	O
chest	chest	NN	I-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
relief	relief	NN	B-NP	O
with	with	IN	B-PP	O
sublingual	sublingual	JJ	B-NP	B-protein
nitrogen	nitrogen	NN	I-NP	I-protein
x	x	SYM	B-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

He	He	PRP	B-NP	O
called	call	VBD	B-VP	O
EMS	EMS	NNP	B-NP	O
who	who	WP	B-NP	O
arrived	arrive	VBD	B-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
scene	scene	NN	I-NP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
the	the	DT	B-NP	O
following	follow	VBG	I-NP	O
code	code	NN	I-NP	O
status	status	NN	I-NP	O
mentioned	mention	VBN	B-VP	O
above	above	RB	B-ADVP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
VF	VF	NN	I-NP	O
arrest	arrest	NN	I-NP	O
and	and	CC	B-NP	O
then	then	RB	I-NP	O
a	a	DT	B-NP	O
PEA	PEA	NN	I-NP	O
arrest	arrest	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
arrival	arrival	NN	B-NP	O
to	to	TO	B-PP	O
Tonwa	Tonwa	NNP	B-NP	O
Medical	Medical	NNP	I-NP	O
Center	Center	NNP	I-NP	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
of	of	IN	B-PP	O
132	132	CD	B-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
89/61	89/61	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
respiratory	respiratory	JJ	B-NP	O
rate	rate	NN	I-NP	O
28	28	CD	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
normal	normal	JJ	B-NP	O
saline	saline	NN	I-NP	O
2	2	CD	B-NP	O
liters	liter	NNS	I-NP	O
,	,	,	O	O
dopamine	dopamine	NN	B-NP	O
drip	drip	NN	I-NP	O
,	,	,	O	O
Lopressor	Lopressor	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
push	push	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
paralyzed	paralyze	VBN	I-VP	O
,	,	,	O	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
point	point	NN	I-NP	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
determined	determine	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
would	would	MD	B-VP	O
likely	likely	RB	I-VP	O
need	need	VB	I-VP	O
urgent	urgent	JJ	B-NP	O
cardiac	cardiac	JJ	I-NP	O
catheterization	catheterization	NN	I-NP	O
for	for	IN	B-PP	O
suspected	suspect	VBN	B-NP	O
myocardial	myocardial	JJ	I-NP	O
infarction	infarction	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
the	the	DT	B-NP	O
Specce	Specce	NNP	I-NP	O
Health	Health	NNP	I-NP	O
Care	Care	NNP	I-NP	O
Cardiac	Cardiac	NNP	I-NP	O
Cath	Cath	NNP	I-NP	O
lab	lab	NN	I-NP	O
emergently	emergently	RB	B-ADVP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
CABG	CABG	NN	I-NP	O
as	as	IN	B-SBAR	O
noted	note	VBN	B-VP	O
above	above	IN	B-PP	O
;	;	:	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
non-Q-wave	non-Q-wave	JJ	I-NP	O
MIs	MI	NNS	I-NP	O
in	in	IN	B-PP	O
1985	1985	CD	B-NP	O
and	and	CC	I-NP	O
subsequently	subsequently	RB	I-NP	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
type	type	NN	I-NP	O
2	2	CD	I-NP	O
,	,	,	O	O
peripheral	peripheral	JJ	B-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
depression	depression	NN	B-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
COPD	COPD	NN	B-NP	O
,	,	,	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
GI	GI	NN	B-NP	O
bleed	bleed	NN	I-NP	O
,	,	,	O	O
peptic	peptic	JJ	B-NP	O
ulcer	ulcer	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
obstructive	obstructive	JJ	B-NP	O
sleep	sleep	NN	I-NP	O
apnea	apnea	NN	I-NP	O
,	,	,	O	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
with	with	IN	B-PP	O
rapid	rapid	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
response	response	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
cholecystectomy	cholecystectomy	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
aortobifem	aortobifem	NN	I-NP	O
bypass	bypass	IN	B-PP	O
graft	graft	NN	B-NP	O
in	in	IN	B-PP	O
1987	1987	CD	B-NP	O
,	,	,	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
transfusion	transfusion	NN	B-NP	O
reaction	reaction	NN	I-NP	O
resulting	result	VBG	B-VP	O
in	in	IN	B-PP	O
hemolysis	hemolysis	NN	B-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
no	no	DT	B-NP	O
known	known	JJ	I-NP	O
medical	medical	JJ	I-NP	O
allergies	allergy	NNS	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
Included	Include	VBN	B-NP	O
insulin	insulin	NN	I-NP	B-protein
,	,	,	O	O
Isordil	Isordil	NN	B-NP	O
,	,	,	O	O
digoxin	digoxin	NN	B-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
folate	folate	NN	B-NP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
,	,	,	O	O
Lipitor	Lipitor	NNP	B-NP	O
,	,	,	O	O
lisinopril	lisinopril	NN	B-NP	O
,	,	,	O	O
metoprolol	metoprolol	NN	B-NP	O
,	,	,	O	O
Protonix	Protonix	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
He	He	PRP	B-NP	B-DNA
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
current	current	JJ	I-NP	O
smoker	smoker	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	B-DNA
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
retired	retired	JJ	I-NP	O
truck	truck	NN	I-NP	O
driver	driver	NN	I-NP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
is	be	VBZ	B-VP	O
married	marry	VBN	I-VP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Significant	Significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
diabetes	diabetes	NN	B-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	JJ	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
:	:	:	O	O
On	On	IN	B-PP	O
presentation	presentation	NN	B-NP	O
to	to	TO	B-PP	O
Thara	Thara	NNP	B-NP	O
Healthcare	Healthcare	NNP	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
pulse	pulse	NN	I-NP	O
of	of	IN	B-PP	O
70	70	CD	B-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
87/54	87/54	CD	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
intubated	intubate	VBN	I-VP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
saturation	saturation	NN	I-NP	O
of	of	IN	B-PP	O
97	97	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
40	40	CD	B-NP	O
%	%	NN	I-NP	O
FiO2	FiO2	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
intubated	intubate	VBN	I-VP	O
and	and	CC	I-VP	O
sedated	sedate	VBN	I-VP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
JVP	JVP	NN	I-NP	B-protein
was	be	VBD	B-VP	O
12	12	CD	B-NP	O
cm	cm	NN	I-NP	O
of	of	IN	B-PP	O
water	water	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
normal	normal	JJ	B-NP	O
S1	S1	NN	I-NP	B-protein
and	and	CC	I-NP	O
S2	S2	NN	I-NP	B-protein
.	.	.	O	O

No	No	DT	B-NP	O
murmurs	murmur	NNS	I-NP	O
,	,	,	O	O
rubs	rub	NNS	B-NP	O
,	,	,	O	O
or	or	CC	O	O
gallops	gallop	NNS	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
mechanical	mechanical	JJ	I-NP	O
S2	S2	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
abdomen	abdoman	NNS	I-NP	O
was	be	VBD	B-VP	O
soft	soft	JJ	B-ADJP	O
,	,	,	O	O
nontender	nontender	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
nondistended	nondistended	JJ	B-ADJP	O
.	.	.	O	O

Bilateral	Bilateral	JJ	B-NP	O
lower	low	JJR	I-NP	O
extremities	extremity	NNS	I-NP	O
were	be	VBD	B-VP	O
cool	cool	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
clammy	clammy	JJ	I-ADJP	O
with	with	IN	B-PP	O
1	1	CD	B-NP	O
+	+	SYM	I-NP	O
DP	DP	NN	I-NP	O
and	and	CC	I-NP	O
PT	PT	NN	I-NP	O
pulses	pulse	NNS	I-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
ecchymosis	ecchymosis	NN	B-NP	O
as	as	IN	B-PP	O
a	a	DT	B-NP	O
result	result	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
use	use	NN	I-NP	O
.	.	.	O	O

Initial	Initial	JJ	B-NP	O
labs	lab	NNS	I-NP	O
were	be	VBD	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
glucose	glucose	NN	I-NP	O
of	of	IN	B-PP	O
220	220	CD	B-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
CK	CK	NN	I-NP	B-protein
of	of	IN	B-PP	O
565	565	CD	B-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
MB	MB	NN	I-NP	O
of	of	IN	B-PP	O
74	74	CD	B-NP	O
and	and	CC	O	O
troponin	troponin	NN	B-NP	O
of	of	IN	B-PP	O
14.0	14.0	CD	B-NP	O
.	.	.	O	O

Hematocrit	Hematocrit	NN	B-NP	O
was	be	VBD	B-VP	O
48	48	CD	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
1.7	1.7	CD	B-NP	O
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
lobe	lobe	NN	I-NP	O
infiltrate	infiltrate	NN	I-NP	O
.	.	.	O	O

EKG	EKG	NN	B-NP	B-protein
with	with	IN	B-PP	O
sinus	sinus	NN	B-NP	O
rhythm	rhythm	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
bundle-branch	bundle-branch	NN	I-NP	O
block	block	NN	I-NP	O
with	with	IN	B-PP	O
right	right	JJ	B-NP	O
axis	axis	NN	I-NP	O
deviation	deviation	NN	I-NP	O
.	.	.	O	O

Also	Also	RB	B-ADVP	O
with	with	IN	B-PP	O
inferior	inferior	JJ	B-NP	O
T-wave	T-wave	NN	I-NP	O
inversions	inversion	NNS	I-NP	O
and	and	CC	O	O
1-mm	1-mm	JJ	B-NP	O
ST	ST	JJ	I-NP	O
elevation	elevation	NN	I-NP	O
in	in	IN	B-PP	O
V3	V3	NN	B-NP	O
and	and	CC	O	O
1-mm	1-mm	JJ	B-NP	O
ST	ST	JJ	I-NP	O
depressions	depression	NNS	I-NP	O
in	in	IN	B-PP	O
I	I	NNP	B-NP	O
and	and	CC	O	O
O.	O.	NNP	B-NP	O
Echocardiogram	Echocardiogram	NNP	I-NP	O
previously	previously	RB	B-ADVP	O
on	on	IN	B-PP	O
3/3	3/3	CD	B-NP	O
revealed	reveal	VBD	B-VP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	B-protein
of	of	IN	B-PP	O
39	39	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
inferior	inferior	JJ	B-NP	O
HK	HK	NN	I-NP	O
and	and	CC	I-NP	O
AK	AK	NN	I-NP	B-protein
,	,	,	O	O
lateral	lateral	JJ	B-NP	O
HK	HK	NN	I-NP	O
,	,	,	O	O
inferoapical	inferoapical	JJ	B-NP	O
DK	DK	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	B-protein
had	have	VBD	B-VP	I-protein
mild	mild	JJ	B-NP	I-protein
MR	MR	NN	I-NP	I-protein
and	and	CC	O	O
aortic	aortic	JJ	B-NP	O
radiant	radiant	NN	I-NP	O
of	of	IN	B-PP	O
27/16	27/16	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
right	right	JJ	I-NP	O
ventricular	ventricular	JJ	I-NP	O
systolic	systolic	JJ	I-NP	O
function	function	NN	I-NP	O
is	be	VBZ	B-VP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

In	In	IN	B-PP	O
summary	summary	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
60-year-old	60-year-old	JJ	I-NP	O
male	male	NN	I-NP	O
with	with	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
now	now	RB	B-ADVP	O
status	status	NN	B-NP	O
post	post	IN	B-PP	O
a	a	DT	B-NP	O
VF	VF	NN	I-NP	O
arrest	arrest	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
non-Q-wave	non-Q-wave	JJ	B-NP	O
myocardial	myocardial	JJ	I-NP	O
infarction	infarction	NN	I-NP	O
with	with	IN	B-PP	O
isolated	isolate	VBN	B-NP	O
ST	ST	NN	I-NP	O
elevation	elevation	NN	I-NP	O
in	in	IN	B-PP	O
V3	V3	NN	B-NP	B-protein
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
critical	critical	JJ	B-NP	O
care	care	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Cardiac	Cardiac	NNP	I-NP	O
Intensive	Intensive	NNP	I-NP	O
Care	Care	NNP	I-NP	O
Unit	Unit	NNP	I-NP	O
at	at	IN	B-PP	O
Lungken	Lungken	NNP	B-NP	O
Medical	Medical	NNP	I-NP	O
Center	Center	NNP	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
BY	BY	NN	I-NP	O
PROBLEM	PROBLEM	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
Ischemia	Ischemia	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
emergently	emergently	RB	B-ADVP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
cardiac	cardiac	JJ	I-NP	B-protein
catheterization	catheterization	NN	I-NP	I-protein
lab	lab	NN	I-NP	I-protein
where	where	WRB	B-ADVP	O
catheterization	catheterization	NN	B-NP	O
revealed	reveal	VBD	B-VP	O
severe	severe	JJ	B-NP	O
native	native	JJ	I-NP	O
3VD	3VD	NN	I-NP	O
and	and	CC	I-NP	O
vein	vein	NN	I-NP	O
graft	graft	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	B-protein
left	left	JJ	I-NP	I-protein
main	main	NN	I-NP	I-protein
is	be	VBZ	B-VP	O
moderately	moderately	RB	I-VP	O
sized	size	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
distal	distal	JJ	I-NP	O
60	60	CD	I-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
mid	mid	JJ	I-NP	O
LAD	LAD	NN	I-NP	O
was	be	VBD	B-VP	O
proximally	proximally	RB	I-VP	O
occluded	occlude	VBN	I-VP	O
after	after	IN	B-PP	O
the	the	DT	B-NP	O
first	first	JJ	I-NP	O
septa	septa	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
left	left	JJ	I-NP	O
circumference	circumference	NN	I-NP	O
is	be	VBZ	B-VP	O
proximally	proximally	RB	I-VP	O
occluded	occlude	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
distal	distal	JJ	I-NP	O
LAD	LAD	NN	I-NP	O
after	after	IN	B-PP	O
vein	vein	NN	B-NP	O
graft	graft	NN	I-NP	O
is	be	VBZ	B-VP	O
without	without	IN	B-PP	O
significant	significant	JJ	B-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
distal	distal	JJ	I-NP	O
OM	OM	NN	I-NP	O
branch	branch	NN	I-NP	O
after	after	IN	B-PP	O
the	the	DT	B-NP	O
vein	vein	NN	I-NP	O
graft	graft	NN	I-NP	O
is	be	VBZ	B-VP	O
diffusely	diffusely	RB	I-VP	O
diseased	disease	VBN	I-VP	O
with	with	IN	B-PP	O
focal	focal	JJ	B-NP	O
99	99	CD	I-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
after	after	IN	B-PP	O
the	the	DT	B-NP	O
distal	distal	JJ	I-NP	O
anastomosis	anastomosis	NN	I-NP	O
.	.	.	O	O

Saphenous	Saphenous	JJ	B-NP	O
vein	vein	NN	I-NP	O
graft	graft	NN	I-NP	O
to	to	TO	B-PP	O
LAD	LAD	NN	B-NP	B-protein
is	be	VBZ	B-VP	O
patent	patent	JJ	B-NP	O
,	,	,	I-NP	O
saphenous	saphenous	JJ	I-NP	O
vein	vein	NN	I-NP	O
graft	graft	NN	I-NP	O
to	to	TO	B-PP	O
OM	OM	NN	B-NP	O
has	have	VBZ	B-VP	O
99	99	CD	B-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
in	in	IN	B-PP	O
distal	distal	JJ	B-NP	O
anastomosis	anastomosis	NN	I-NP	O
with	with	IN	B-PP	O
_____	_____	NN	B-NP	O
flow	flow	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
tilting	tilting	JJ	I-NP	O
disk	disk	NN	I-NP	O
aortic	aortic	JJ	I-NP	O
valve	valve	NN	I-NP	O
that	that	WDT	B-NP	O
appears	appear	VBZ	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
functioning	function	VBG	I-VP	O
normally	normally	RB	B-ADVP	O
.	.	.	O	O

In	In	IN	B-PP	O
summary	summary	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
what	what	WP	B-NP	O
was	be	VBD	B-VP	O
considered	consider	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
a	a	DT	B-NP	O
nonintervenable	nonintervenable	JJ	I-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
thus	thus	RB	B-ADVP	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
medical	medical	JJ	B-NP	O
management	management	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
received	receive	VBD	B-VP	O
optimal	optimal	JJ	B-NP	O
medical	medical	JJ	I-NP	O
management	management	NN	I-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
acute	acute	JJ	I-NP	O
myocardial	myocardial	JJ	I-NP	O
infarction	infarction	NN	I-NP	O
including	include	VBG	B-PP	O
aspirin	aspirin	NN	B-NP	O
and	and	CC	I-NP	O
Plavix	Plavix	NN	I-NP	O
,	,	,	O	O
statin	statin	NN	B-NP	O
,	,	,	O	O
beta-blocker	beta-blocker	NN	B-NP	O
,	,	,	O	O
ACE	ACE	NN	B-NP	O
inhibitor	inhibitor	NN	I-NP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-VP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
ischemic	ischemic	JJ	I-NP	O
EKG	EKG	NN	I-NP	O
changes	change	NNS	I-NP	O
have	have	VBP	B-VP	O
resolved	resolve	VBN	I-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
transfer	transfer	NN	B-NP	O
out	out	IN	B-PP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
Coronary	Coronary	NNP	I-NP	O
Care	Care	NNP	I-NP	O
Unit	Unit	NNP	I-NP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
chest	chest	NN	B-NP	O
pain-free	pain-free	JJ	B-ADJP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
remainder	remainder	NN	I-NP	O
of	of	IN	B-PP	O
that	that	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
CK	CK	NN	I-NP	B-protein
peaked	peak	VBD	B-VP	O
at	at	IN	B-PP	O
1090	1090	CD	B-NP	O
on	on	IN	B-PP	O
6/17/03	6/17/03	CD	B-NP	O
.	.	.	O	O

Pump	Pump	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
anticoagulated	anticoagulate	VBN	I-VP	O
with	with	IN	B-PP	O
heparin	heparin	NN	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
goal	goal	NN	I-NP	O
PTT	PTT	NN	I-NP	O
of	of	IN	B-PP	O
6084	6084	CD	B-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
Bjork-Shiley	Bjork-Shiley	NNP	I-NP	O
valve	valve	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
TTE	TTE	NN	I-NP	O
on	on	IN	B-PP	O
6/17/03	6/17/03	CD	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
ventricular	ventricular	JJ	I-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
25	25	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
inferoposterior	inferoposterior	JJ	B-NP	O
HK	HK	NN	I-NP	O
,	,	,	O	O
left	leave	VBD	B-VP	O
atrial	atrial	JJ	B-NP	O
enlargement	enlargement	NN	I-NP	O
,	,	,	O	O
mild	mild	JJ	B-ADJP	O
to	to	TO	B-PP	O
moderate	moderate	JJ	B-NP	O
MR	MR	NN	I-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
well-seated	well-seated	JJ	B-NP	O
AVR	AVR	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
rapidly	rapidly	RB	I-VP	O
weaned	wean	VBN	I-VP	O
off	off	RP	B-PRT	O
dopamine	dopamine	NN	B-NP	O
and	and	CC	I-NP	O
Neo-Synephrine	Neo-Synephrine	NN	I-NP	O
during	during	IN	B-PP	O
his	his	PRP$	B-NP	O
ICU	ICU	NN	I-NP	O
stay	stay	NN	I-NP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
out	out	RP	B-PRT	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
floor	floor	NN	I-NP	O
,	,	,	O	O
once	once	IN	B-SBAR	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
considered	consider	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
euvolemic	euvolemic	JJ	B-ADJP	O
.	.	.	O	O

Rhythm	Rhythm	NN	B-NP	O
:	:	:	O	O
As	As	IN	B-SBAR	O
noted	note	VBN	B-VP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
admitted	admit	VBN	B-VP	O
with	with	IN	B-PP	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
VF	VF	NN	I-NP	O
arrest	arrest	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
successfully	successfully	RB	I-VP	O
defibrillated	defibrillate	VBN	I-VP	O
out	out	IN	B-PP	O
of	of	IN	B-PP	O
that	that	DT	B-NP	O
with	with	IN	B-PP	O
shock	shock	NN	B-NP	B-protein
x	x	SYM	B-NP	I-protein
1	1	CD	I-NP	I-protein
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
course	course	NN	I-NP	O
was	be	VBD	B-VP	O
complicated	complicate	VBN	I-VP	O
by	by	IN	B-PP	O
an	an	DT	B-NP	O
episode	episode	NN	I-NP	O
of	of	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
with	with	IN	B-PP	O
rapid	rapid	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
rate	rate	NN	I-NP	O
up	up	IN	B-PP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
160s	160	NNS	I-NP	B-DNA
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
hypotension	hypotension	NN	B-NP	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
electively	electively	RB	I-VP	O
cardioverted	cardioverte	VBN	I-VP	O
with	with	IN	B-PP	O
shock	shock	NN	B-NP	O
x	x	SYM	B-NP	O
1	1	CD	I-NP	O
to	to	TO	B-PP	O
normal	normal	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
after	after	IN	B-PP	O
which	which	WDT	B-NP	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
loaded	load	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
10-g	10-g	JJ	I-NP	O
amio	amio	NN	I-NP	O
load	load	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
he	he	PRP	B-NP	O
has	have	VBZ	B-VP	O
remained	remain	VBN	I-VP	O
in	in	IN	B-PP	O
normal	normal	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
since	since	IN	B-PP	O
that	that	DT	B-NP	O
episode	episode	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
after	after	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
floor	floor	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
,	,	,	O	O
he	he	PRP	B-NP	O
received	receive	VBD	B-VP	O
a	a	DT	B-NP	O
single	single	JJ	I-NP	O
lead	lead	NN	I-NP	O
AICD	AICD	NN	I-NP	O
given	give	VBN	B-VP	O
his	his	PRP$	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
dilated	dilated	JJ	B-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
,	,	,	O	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
VF	VF	NN	I-NP	O
arrest	arrest	NN	I-NP	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
intubated	intubate	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
CCU	CCU	NN	I-NP	O
for	for	IN	B-PP	O
airway	airway	NN	B-NP	O
protection	protection	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
rapidly	rapidly	RB	I-VP	O
weaned	wean	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
sedation	sedation	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
successfully	successfully	RB	I-VP	O
extubated	extubate	VBN	I-VP	O
on	on	IN	B-PP	O
1/28/03	1/28/03	CD	B-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
his	his	PRP$	B-NP	B-DNA
chest	ch	JJS	I-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
was	be	VBD	B-VP	O
complicated	complicate	VBN	I-VP	O
by	by	IN	B-PP	O
left	left	JJ	B-NP	O
lower	low	JJR	I-NP	O
lobe	lobe	NN	I-NP	O
infiltrate	infiltrate	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
concerning	concern	VBG	I-VP	O
for	for	IN	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
ultimately	ultimately	RB	B-ADVP	O
has	have	VBZ	B-VP	O
sputum	sputum	NN	B-NP	O
culture	culture	NN	I-NP	O
that	that	WDT	B-NP	O
grew	grow	VBD	B-VP	O
out	out	RP	B-PRT	O
pseudomonas	pseudomona	NNS	B-NP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
14-day	14-day	JJ	I-NP	O
course	course	NN	I-NP	O
for	for	IN	B-PP	O
pseudomonal	pseudomonal	JJ	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
.	.	.	O	O

Please	Please	VB	B-VP	O
see	see	VB	I-VP	O
ID	ID	NN	B-NP	O
section	section	NN	I-NP	O
below	below	IN	B-PP	O
for	for	IN	B-PP	O
more	more	JJR	B-NP	O
details	detail	NNS	I-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
with	with	IN	B-PP	O
hypotension	hypotension	NN	B-NP	O
and	and	CC	I-NP	O
question	question	NN	I-NP	O
of	of	IN	B-PP	O
sepsis	sepsis	NN	B-NP	O
,	,	,	O	O
septic	septic	JJ	B-NP	O
physiology	physiology	NN	I-NP	O
on	on	IN	B-PP	O
1/28/03	1/28/03	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
empiric	empiric	JJ	B-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
and	and	CC	I-NP	O
Flagyl	Flagyl	NN	I-NP	O
for	for	IN	B-PP	O
question	question	NN	B-NP	O
aspiration	aspiration	NN	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
by	by	IN	B-PP	O
chest	chest	NN	B-NP	O
x-ray	x-ray	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
given	give	VBN	I-VP	O
one	one	CD	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
gentamicin	gentamicin	NN	B-NP	O
and	and	CC	O	O
then	then	RB	B-ADVP	O
covered	cover	VBD	B-VP	O
his	his	PRP$	B-NP	O
broad	broad	NN	I-NP	O
into	into	IN	B-PP	O
ceftaz	ceftaz	NN	B-NP	O
,	,	,	O	O
vanc	vanc	NN	B-NP	O
,	,	,	O	O
levo	levo	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Flagyl	Flagyl	NN	B-NP	O
while	while	IN	B-SBAR	O
awaiting	await	VBG	B-VP	O
results	result	NNS	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
ultimately	ultimately	RB	B-ADVP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
growth	growth	NN	I-NP	O
from	from	IN	B-PP	O
any	any	DT	B-NP	O
blood	blood	NN	I-NP	O
cultures	culture	NNS	I-NP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
on	on	IN	B-PP	O
sputum	sputum	NN	B-NP	O
culture	culture	NN	I-NP	O
positive	positive	JJ	B-ADJP	O
for	for	IN	B-PP	O
pseudomonas	pseudomona	NNS	B-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
sensitive	sensitive	JJ	B-ADJP	O
to	to	TO	B-VP	O
ceftazidime	ceftazidime	VB	I-VP	O
,	,	,	O	O
but	but	CC	O	O
resistant	resistant	JJ	B-ADJP	O
to	to	TO	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
ultimately	ultimately	RB	I-VP	O
switched	switch	VBN	I-VP	O
over	over	RP	B-PRT	O
to	to	TO	B-PP	O
single	single	JJ	B-NP	O
agent	agent	NN	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
total	total	NN	I-NP	O
of	of	IN	B-PP	O
14-day	14-day	JJ	B-NP	O
course	course	NN	I-NP	O
for	for	IN	B-PP	O
pseudomonal	pseudomonal	JJ	B-NP	O
pneumonia/bronchitis	pneumonia/bronchitis	NN	I-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
baseline	baseline	NN	I-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
1.6	1.6	CD	B-NP	O
and	and	CC	I-NP	O
2.0	2.0	CD	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
Intensive	Intensive	JJ	I-NP	O
Care	Care	NNP	I-NP	O
Unit	Unit	NNP	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
rise	rise	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
up	up	IN	B-PP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
peak	peak	NN	I-NP	O
of	of	IN	B-PP	O
2.8	2.8	CD	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
still	still	RB	B-ADVP	O
has	have	VBZ	B-VP	O
slightly	slightly	RB	B-NP	O
elevated	elevated	JJ	I-NP	O
creatinine	creatinine	NN	I-NP	O
at	at	IN	B-PP	O
2.2	2.2	CD	B-NP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
it	it	PRP	B-NP	O
seems	seem	VBZ	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
normalizing	normalize	VBG	I-VP	O
.	.	.	O	O

It	It	PRP	B-NP	O
is	be	VBZ	B-VP	O
likely	likely	JJ	B-ADJP	O
that	that	IN	B-SBAR	O
this	this	DT	B-NP	O
is	be	VBZ	B-VP	O
contributed	contribute	VBN	I-VP	O
by	by	IN	B-PP	O
his	his	PRP$	B-NP	O
Dilaudid	Dilaudid	NNP	I-NP	O
received	receive	VBD	B-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
catheterization	catheterization	NN	B-NP	O
.	.	.	O	O

Heme	Heme	NN	B-NP	B-protein
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
anticoagulated	anticoagulate	VBN	B-VP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
with	with	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
and	and	CC	O	O
then	then	RB	B-ADVP	O
during	during	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
with	with	IN	B-PP	O
unfractionated	unfractionated	JJ	B-NP	O
heparin	heparin	NN	I-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
Bjork-Shiley	Bjork-Shiley	NNP	I-NP	O
valve	valve	VBP	B-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
goal	goal	NN	I-NP	O
PTT	PTT	NN	I-NP	O
of	of	IN	B-PP	O
60	60	CD	B-NP	O
to	to	TO	B-PP	O
80	80	CD	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
is	be	VBZ	B-VP	O
being	be	VBG	I-VP	O
recoumadinized	recoumadinize	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
goal	goal	NN	I-NP	O
INR	INR	NN	I-NP	O
of	of	IN	B-PP	O
2.5	2.5	CD	B-NP	O
to	to	TO	B-PP	O
3.5	3.5	CD	B-NP	O
.	.	.	O	O

Previously	Previously	RB	B-ADVP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
2	2	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
his	his	PRP$	B-NP	O
heparin	heparin	NN	I-NP	O
dripped	drip	VBD	B-VP	O
to	to	TO	B-PP	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
therapeutically	therapeutically	RB	B-ADVP	O
with	with	IN	B-PP	O
PTT	PTT	NN	B-NP	O
60	60	CD	I-NP	O
to	to	TO	B-PP	O
80	80	CD	B-NP	O
until	until	IN	B-SBAR	O
his	his	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
is	be	VBZ	B-VP	O
therapeutic	therapeutic	JJ	B-ADJP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

Hematology	Hematology	NN	B-NP	O
continued	continue	VBD	B-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
macrocytic	macrocytic	JJ	I-NP	O
anemia	anemia	NN	I-NP	O
,	,	,	O	O
currently	currently	RB	B-ADVP	O
on	on	IN	B-PP	O
folate	folate	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
labs	lab	NNS	I-NP	O
were	be	VBD	B-VP	O
pending	pende	VBG	B-ADJP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
B12	B12	NN	I-NP	B-protein
level	level	NN	I-NP	O
,	,	,	O	O
methylmalonic	methylmalonic	JJ	B-NP	O
acid	acid	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
homocysteine	homocysteine	NN	B-NP	O
did	do	VBD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
up	up	RP	B-PRT	O
while	while	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
at	at	IN	B-PP	O
rehab	rehab	NN	B-NP	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
with	with	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
NPH	NPH	NN	B-NP	B-protein
with	with	IN	B-PP	O
a	a	DT	B-NP	O
Regular	Regular	JJ	I-NP	O
Insulin	Insulin	NN	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
control	control	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
sugars	sugar	NNS	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
should	should	MD	B-VP	O
remain	remain	VB	I-VP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
NPH	NPH	NN	I-NP	B-protein
with	with	IN	B-PP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
coverage	coverage	NN	I-NP	O
.	.	.	O	O

FEN	FEN	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
ADA	ADA	NN	B-NP	O
diet	diet	NN	I-NP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
electrolytes	electrolyte	NNS	I-NP	O
were	be	VBD	B-VP	O
repleted	replete	VBN	I-VP	O
p.r.n.	p.r.n.	IN	B-PP	O
Prophylaxis	Prophylaxis	NNP	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
on	on	IN	B-PP	O
therapeutic	therapeutic	JJ	B-NP	O
anticoagulation	anticoagulation	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
proton	proton	NN	I-NP	O
pump	pump	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
for	for	IN	B-PP	O
symptomatic	symptomatic	JJ	B-NP	O
GERD	GERD	NN	I-NP	O
.	.	.	O	O

Tubes	Tube	NNS	B-NP	O
,	,	,	O	O
lines	line	NNS	B-NP	O
,	,	,	O	O
and	and	CC	O	O
drains	drain	NNS	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
NG	NG	NN	I-NP	O
tube	tube	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
short	short	JJ	I-NP	O
time	time	NN	I-NP	O
during	during	IN	B-PP	O
his	his	PRP$	B-NP	O
Intensive	Intensive	JJ	I-NP	O
Care	Care	NNP	I-NP	O
Unit	Unit	NNP	I-NP	O
stay	stay	NN	I-NP	O
while	while	IN	B-SBAR	O
was	be	VBD	B-VP	O
intubated	intubate	VBN	I-VP	O
for	for	IN	B-PP	O
enteral	enteral	JJ	B-NP	O
feeding	feeding	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
removed	remove	VBN	I-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
take	take	VB	I-VP	O
adequate	adequate	JJ	B-NP	O
p.o.	p.o.	NN	I-NP	O
intake	intake	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
he	he	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
dual	dual	JJ	I-NP	O
lumen	lumen	NN	I-NP	O
peripherally	peripherally	RB	B-ADVP	O
inserted	insert	VBD	B-VP	O
central	central	JJ	B-NP	O
catheter	catheter	NN	I-NP	O
placed	place	VBN	B-VP	O
in	in	IN	B-PP	O
his	his	PRP$	B-NP	O
right	right	JJ	I-NP	O
antecubital	antecubital	JJ	I-NP	O
fossa	fossa	NN	I-NP	O
on	on	IN	B-PP	O
3/9/03	3/9/03	CD	B-NP	O
for	for	IN	B-PP	O
intravenous	intravenous	JJ	B-NP	O
access	access	NN	I-NP	O
for	for	IN	B-PP	O
IV	IV	CD	B-NP	O
heparin	heparin	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
to	to	TO	B-VP	O
continue	continue	VB	I-VP	O
his	his	PRP$	B-NP	O
14-day	14-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
ceftazidime	ceftazidime	NN	B-NP	O
.	.	.	O	O

Pertinent	Pertinent	JJ	B-NP	B-protein
labs	lab	NNS	I-NP	I-protein
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
include	include	VBP	B-VP	O
a	a	DT	B-NP	O
BUN	BUN	NN	I-NP	O
of	of	IN	B-PP	O
53	53	CD	B-NP	O
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
of	of	IN	B-PP	O
2.2	2.2	CD	B-NP	O
,	,	,	O	O
white	white	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
11.4	11.4	CD	B-NP	O
with	with	IN	B-PP	O
73	73	CD	B-NP	O
%	%	NN	I-NP	O
polys	poly	NNS	I-NP	O
,	,	,	O	O
20	20	CD	B-NP	O
%	%	NN	I-NP	O
lymphocytes	lymphocyte	NNS	I-NP	O
,	,	,	O	O
6	6	CD	B-NP	O
%	%	NN	I-NP	O
monos	mono	NNS	I-NP	O
,	,	,	O	O
2	2	CD	B-NP	O
%	%	NN	I-NP	O
eosinophils	eosinophil	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
1	1	CD	B-NP	O
%	%	NN	I-NP	O
basophils	basophil	NNS	I-NP	B-cell_type
.	.	.	O	O

Hematocrit	Hematocrit	NN	B-NP	O
of	of	IN	B-PP	O
33.3	33.3	CD	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
stable	stable	JJ	B-ADJP	O
,	,	,	O	O
platelets	platelet	NNS	B-NP	B-cell_type
of	of	IN	B-PP	O
175	175	CD	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
MCV	MCV	NN	I-NP	O
was	be	VBD	B-VP	O
96.8	96.8	CD	B-NP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
RDW	RDW	NN	I-NP	B-protein
was	be	VBD	B-VP	O
18.0	18.0	CD	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
last	last	JJ	I-NP	O
PTT	PTT	NN	I-NP	O
was	be	VBD	B-VP	O
66.1	66.1	CD	B-NP	O
and	and	CC	O	O
INR	INR	NN	B-NP	B-protein
was	be	VBD	B-VP	O
1.3	1.3	CD	B-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
AT	AT	IN	B-PP	O
THE	THE	DT	B-NP	O
TIME	TIME	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
amiodarone	amiodarone	NN	I-NP	O
load	load	NN	I-NP	O
400	400	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
t.i.d.	t.i.d.	FW	I-ADVP	O
x	x	SYM	O	O
3	3	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
last	last	JJ	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
dosing	dosing	NN	I-NP	O
scheduled	schedule	VBN	B-VP	O
4/3/03	4/3/03	CD	B-NP	O
;	;	:	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
400	400	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
x	x	SYM	O	O
7	7	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
last	last	JJ	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
dose	dose	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
4/30/03	4/30/03	CD	B-NP	O
;	;	:	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	I-VP	O
amiodarone	amiodarone	VB	I-VP	O
400	400	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
starting	start	VBG	B-VP	O
on	on	IN	B-PP	O
2/26/03	2/26/03	CD	B-NP	O
and	and	CC	O	O
is	be	VBZ	B-VP	O
to	to	TO	I-VP	O
remain	remain	VB	I-VP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
dose	dose	NN	I-NP	O
indefinitely	indefinitely	RB	B-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Enteric-coated	Enteric-coated	JJ	B-NP	O
aspirin	aspirin	NN	I-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
3	3	CD	I-NP	O
.	.	.	O	O

Ceftazidime	Ceftazidime	NN	B-NP	O
2	2	CD	I-NP	O
g	g	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
12h	12h	NN	I-NP	O
.	.	.	O	O

x	x	SYM	O	O
14	14	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
last	last	JJ	B-NP	O
dose	dose	NN	I-NP	O
on	on	IN	B-PP	O
10/6/03	10/6/03	CD	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
5	5	CD	I-NP	O
.	.	.	O	O

Folate	Folate	NN	B-NP	B-protein
1	1	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
q.d.	q.d.	NN	I-NP	I-protein
6	6	CD	I-NP	I-protein
.	.	.	O	O

Lasix	Lasix	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
new	new	JJ	I-NP	O
baseline	baseline	NN	I-NP	O
diuretic	diuretic	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Heparin	Heparin	NN	B-NP	O
GTT	GTT	NN	I-NP	O
infusion	infusion	NN	I-NP	O
,	,	,	O	O
current	current	JJ	B-NP	O
rate	rate	NN	I-NP	O
900	900	CD	B-NP	O
units	unit	NNS	I-NP	O
per	per	IN	B-PP	O
hour	hour	NN	B-NP	O
,	,	,	O	O
continuous	continuous	JJ	B-ADJP	O
.	.	.	O	O

This	This	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
adjusted	adjust	VBN	I-VP	O
to	to	TO	B-VP	O
achieve	achieve	VB	I-VP	O
a	a	DT	B-NP	O
goal	goal	JJ	I-NP	O
PTT	PTT	NN	I-NP	O
of	of	IN	B-PP	O
60	60	CD	B-NP	O
to	to	TO	B-PP	O
80	80	CD	B-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

NPH	NPH	NN	B-NP	O
insulin	insulin	NN	I-NP	O
15	15	CD	B-NP	O
units	unit	NNS	I-NP	O
subcu	subcu	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
,	,	,	O	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
subcu	subcu	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
has	have	VBZ	B-VP	O
Regular	Regular	JJ	B-NP	B-protein
Insulin	Insulin	NN	I-NP	I-protein
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
subcu	subcu	NN	I-NP	O
q.a.c.	q.a.c.	NN	I-NP	O
and	and	CC	O	O
h.s.	h.s.	NN	B-NP	O
scale	scale	NN	I-NP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
200	200	CD	B-NP	O
,	,	,	O	O
give	give	VB	B-VP	O
0	0	CD	B-NP	O
units	unit	NNS	I-NP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
of	of	IN	B-PP	O
201-250	201-250	CD	B-NP	O
,	,	,	O	O
give	give	VB	B-VP	O
4	4	CD	B-NP	O
units	unit	NNS	I-NP	O
subcu	subcu	NN	B-NP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
251-300	251-300	CD	B-NP	O
,	,	,	O	O
give	give	VB	B-VP	O
6	6	CD	B-NP	O
units	unit	NNS	I-NP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
301-350	301-350	CD	B-NP	O
,	,	,	O	O
give	give	VB	B-VP	O
8	8	CD	B-NP	O
units	unit	NNS	I-NP	O
subcu	subcu	NN	I-NP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
351-400	351-400	CD	B-NP	O
give	give	VB	B-VP	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
subcu	subcu	NN	B-NP	O
and	and	CC	O	O
call	call	VB	B-VP	O
health	health	NN	B-NP	O
officer	officer	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Lopressor	Lopressor	NN	B-NP	O
12.5	12.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

hold	hold	VB	B-NP	O
for	for	IN	B-PP	O
systolic	systolic	JJ	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
85	85	CD	B-NP	O
,	,	,	O	O
pulse	pulse	NN	B-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
50	50	CD	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
may	may	MD	B-VP	O
be	be	VB	I-VP	O
converted	convert	VBN	I-VP	O
over	over	RP	B-PRT	O
to	to	TO	B-PP	O
once	once	RB	O	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
form	form	NN	I-NP	O
of	of	IN	B-PP	O
metoprolol	metoprolol	NN	B-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
discretion	discretion	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
accepting	accept	VBG	I-NP	O
physician	physician	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
would	would	MD	B-VP	O
not	not	RB	I-VP	O
convert	convert	VB	I-VP	O
to	to	TO	B-PP	O
atenolol	atenolol	NN	B-NP	O
given	give	VBN	B-PP	O
the	the	DT	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Nitroglycerin	Nitroglycerin	NN	B-NP	O
0.4	0.4	CD	I-NP	O
mg	mg	NN	I-NP	O
one	one	CD	B-NP	O
tablet	tablet	NN	I-NP	B-DNA
sublingual	sublingual	JJ	I-NP	I-DNA
q.	q.	NN	I-NP	I-DNA
5	5	CD	B-NP	I-DNA
minutes	minute	NNS	I-NP	I-DNA
x	x	SYM	B-NP	I-DNA
3	3	CD	I-NP	I-DNA
for	for	IN	B-PP	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Senna	Senna	NNP	B-NP	O
tablets	tablet	VBZ	B-VP	O
2	2	CD	B-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
12	12	CD	I-NP	O
.	.	.	O	O

Multivitamin	Multivitamin	NN	B-NP	O
therapeutic	therapeutic	JJ	B-ADJP	O
with	with	IN	B-PP	O
minerals	mineral	NNS	B-NP	O
one	one	CD	B-NP	O
tablet	tablet	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
13	13	CD	I-NP	O
.	.	.	O	O

Coumadin	Coumadin	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
x	x	SYM	B-NP	O
3	3	CD	B-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
INR	INR	NN	B-NP	B-protein
checked	check	VBN	B-VP	O
daily	daily	RB	B-ADVP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
load	load	NN	I-NP	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
point	point	NN	I-NP	O
once	once	IN	B-PP	O
his	his	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
is	be	VBZ	B-VP	O
therapeutic	therapeutic	JJ	B-ADJP	O
he	he	PRP	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
what	what	WP	B-NP	O
is	be	VBZ	B-VP	O
suspected	suspect	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
his	his	PRP$	B-NP	O
home	home	NN	I-NP	O
Coumadin	Coumadin	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
2	2	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
14	14	CD	I-NP	O
.	.	.	O	O

Keflex	Keflex	NNP	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
x	x	SYM	O	O
3	3	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
last	last	JJ	B-NP	O
dose	dose	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
on	on	IN	B-PP	O
4/3/03	4/3/03	CD	B-NP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Zocor	Zocor	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
16	16	CD	I-NP	O
.	.	.	O	O

Plavix	Plavix	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
17	17	CD	I-NP	O
.	.	.	O	O

Nexium	Nexium	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
18	18	CD	I-NP	O
.	.	.	O	O

Tylenol	Tylenol	NN	B-NP	O
650	650	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.4-6h	q.4-6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

19	19	CD	B-NP	O
.	.	.	O	O

Dulcolax	Dulcolax	IN	B-PP	O
5	5	CD	B-NP	O
mg	mg	NN	I-NP	O
to	to	TO	B-PP	O
10	10	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.d.	q.d.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
constipation	constipation	NN	I-NP	O
.	.	.	O	O

20	20	CD	B-NP	O
.	.	.	O	O

Morphine	Morphine	NN	B-NP	O
sulfate	sulfate	NN	I-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
to	to	TO	B-PP	O
2	2	CD	B-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

21	21	CD	B-NP	O
.	.	.	O	O

Percocet	Percocet	IN	B-PP	O
one	one	CD	B-NP	O
to	to	TO	I-NP	O
two	two	CD	I-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.4-6h	q.4-6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

22	22	CD	B-NP	O
.	.	.	O	O

Trazodone	Trazodone	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.h.s.	q.h.s.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
insomnia	insomnia	NN	I-NP	O
.	.	.	O	O

23	23	CD	B-NP	O
.	.	.	O	O

Atrovent	Atrovent	NNP	B-NP	O
nebulizer	nebulizer	IN	B-PP	O
0.5	0.5	CD	B-NP	O
mg	mg	NN	I-NP	O
nebulized	nebulize	VBD	B-VP	O
q.i.d.	q.i.d.	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
wheezing	wheezing	NN	I-NP	O
.	.	.	O	O

FUTURE	FUTURE	NN	B-NP	O
CARE	CARE	NN	I-NP	O
:	:	:	O	O
It	It	PRP	B-NP	O
is	be	VBZ	B-VP	O
recommended	recommend	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
be	be	VB	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
low-dose	low-dose	JJ	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
once	once	IN	B-SBAR	O
his	his	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
has	have	VBZ	B-VP	O
stabilized	stabilize	VBN	I-VP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
may	may	MD	B-VP	O
benefit	benefit	VB	I-VP	O
from	from	IN	B-PP	O
further	further	JJ	B-NP	O
afterload	afterload	JJ	I-NP	O
reduction	reduction	NN	I-NP	O
with	with	IN	B-PP	O
nitrates	nitrate	NNS	B-NP	O
including	include	VBG	B-PP	O
Isordil	Isordil	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
the	the	DT	B-NP	O
following	follow	VBG	I-NP	O
followup	followup	NN	I-NP	O
appointment	appointment	NN	I-NP	O
already	already	RB	B-VP	O
arranged	arrange	VBN	I-VP	O
.	.	.	O	O

1	1	LS	B-LST	O
.	.	.	O	O

With	With	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Mauro	Mauro	NNP	I-NP	O
Wisham	Wisham	NNP	I-NP	O
at	at	IN	B-PP	O
Sonri	Sonri	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
his	his	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
and	and	CC	O	O
this	this	DT	B-NP	O
is	be	VBZ	B-VP	O
also	also	RB	B-ADVP	O
the	the	DT	B-NP	O
physician	physician	NN	I-NP	O
who	who	WP	B-NP	O
follows	follow	VBZ	B-VP	O
his	his	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
on	on	IN	B-PP	O
1/20/03	1/20/03	CD	B-NP	O
at	at	IN	B-PP	O
11	11	CD	B-NP	O
:	:	:	O	O
30	30	CD	B-NP	O
a.m.	a.m.	RB	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
q.o.d.	q.o.d.	VBN	I-VP	O
INRs	INR	NNS	B-NP	B-protein
drawn	draw	VBN	B-VP	O
x	x	SYM	B-NP	O
3	3	CD	I-NP	O
and	and	CC	O	O
then	then	RB	O	O
q.	q.	NN	B-NP	B-protein
week	week	NN	I-NP	I-protein
INRs	INR	NNS	I-NP	I-protein
x	x	CC	O	I-protein
4	4	CD	B-NP	I-protein
with	with	IN	B-PP	O
the	the	DT	B-NP	O
results	result	NNS	I-NP	O
reported	report	VBN	B-VP	O
to	to	TO	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Biez	Biez	NNP	I-NP	O
for	for	IN	B-PP	O
adjustment	adjustment	NN	B-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
dose	dose	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
,	,	,	O	O
He	He	PRP	B-NP	O
also	also	RB	B-ADVP	O
has	have	VBZ	B-VP	O
followup	followup	NN	B-NP	O
appointment	appointment	NN	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Damien	Damien	NNP	I-NP	O
Kory	Kory	NNP	I-NP	O
Corria	Corria	NNP	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
cardiologist	cardiologist	NN	I-NP	O
at	at	IN	B-PP	O
Risestrop	Risestrop	NN	B-NP	O
.	.	.	O	O

Followup	Followup	NN	B-NP	O
is	be	VBZ	B-VP	O
arranged	arrange	VBN	I-VP	O
for	for	IN	B-PP	O
8/23/03	8/23/03	CD	B-NP	O
at	at	IN	B-PP	O
4	4	CD	B-NP	O
p.m.	p.m.	NN	I-NP	O
3	3	CD	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
has	have	VBZ	B-VP	O
appointment	appointment	NN	B-NP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
Electrophysiology	Electrophysiology	NNP	I-NP	O
Service	Service	NNP	I-NP	O
at	at	IN	B-PP	O
Na	Na	NNP	B-NP	O
Medical	Medical	NNP	I-NP	O
Center	Center	NNP	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Barton	Barton	NNP	I-NP	O
Kivi	Kivi	NNP	I-NP	O
,	,	,	O	O
phone	phone	NN	B-NP	O
number	number	NN	I-NP	O
365-550-8716	365-550-8716	CD	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
have	have	VB	I-VP	O
followup	followup	NN	B-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Mcnelley	Mcnelley	NNP	I-NP	O
at	at	IN	B-PP	O
Electrophysiology	Electrophysiology	NNP	B-NP	O
Clinic	Clinic	NNP	I-NP	O
at	at	IN	B-PP	O
Erre	Erre	NNP	B-NP	O
Health	Health	NNP	I-NP	O
Care	Care	NNP	I-NP	O
on	on	IN	B-PP	O
4/30/03	4/30/03	CD	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
is	be	VBZ	B-VP	O
scheduled	schedule	VBN	I-VP	O
,	,	,	O	O
but	but	CC	O	O
unavailable	unavailable	JJ	B-ADJP	O
to	to	TO	B-PP	O
me	me	PRP	B-NP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

Please	Please	NN	B-NP	O
check	check	NN	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Baniaga	Baniaga	NNP	I-NP	O
's	's	POS	B-NP	O
office	office	NN	I-NP	O
regarding	regarding	NN	I-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
appointment	appointment	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
accepting	accept	VBG	B-VP	O
physician	physician	NN	B-NP	O
should	should	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
on	on	IN	B-PP	O
B12	B12	NN	B-NP	B-protein
level	level	NN	I-NP	O
,	,	,	O	O
urinalysis	urinalysis	NN	B-NP	O
with	with	IN	B-PP	O
urine	urine	NN	B-NP	O
sediment	sediment	NN	I-NP	O
and	and	CC	I-NP	O
urine	urine	NN	I-NP	B-cell_type
eosinophils	eosinophil	NNS	I-NP	I-cell_type
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
methylmalonic	methylmalonic	JJ	B-NP	O
acid	acid	NN	I-NP	O
and	and	CC	I-NP	O
homocystine	homocystine	NN	I-NP	O
levels	level	NNS	I-NP	O
sent	send	VBN	B-VP	O
on	on	IN	B-PP	O
day	day	NN	B-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
for	for	IN	B-PP	O
workup	workup	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
macrocytic	macrocytic	JJ	I-NP	O
anemia	anemia	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
5-1438563	5-1438563	CD	B-NP	O
ISSten	ISSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Eric	Eric	NNP	B-NP	O
Depierre	Depierre	NNP	I-NP	O
M.D.	M.D.	NNP	I-NP	O
WOH	WOH	NNP	I-NP	O
Cardiovascular	Cardiovascular	NNP	I-NP	O
Division	Division	NNP	I-NP	O
Coll	Coll	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Domenic	Domenic	NNP	B-NP	O
Delmar	Delmar	NNP	I-NP	O
Martire	Martire	NNP	I-NP	O
MD	MD	NNP	I-NP	O
Wigard	Wigard	NNP	I-NP	O
Coholl	Coholl	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Oswaldo	Oswaldo	NNP	B-NP	O
Macek	Macek	NNP	I-NP	O
Oswetlove	Oswetlove	NNP	I-NP	O
Valley	Valley	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
Department	Department	NNP	I-NP	O
of	of	IN	B-PP	O
Medicine	Medicine	NNP	B-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
STROMSKI	STROMSKI	NN	B-NP	O
,	,	,	O	O
ALLAN	ALLAN	NNP	B-NP	O
TRUMAN	TRUMAN	NNP	I-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
FRANKE	FRANKE	NNP	B-NP	O
,	,	,	O	O
JACINTO	JACINTO	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
1188272	1188272	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
8/16/03	8/16/03	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
8/16/03	8/16/03	CD	B-NP	O

